<DOC>
	<DOCNO>NCT00932165</DOCNO>
	<brief_summary>The objective surveillance collect information 1 ) adverse drug reaction expect LPD ( unknown adverse drug reaction ) , 2 ) incidence adverse drug reaction surveillance , 3 ) factor consider affect safety and/or efficacy drug .</brief_summary>
	<brief_title>Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin</brief_title>
	<detailed_description>All patient investigator prescribes first Exemestane ( Aromasin ) register .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Subjects postmenopausal breast cancer ( include ovariectomy etc. ) . Patients evaluated.For example , administer Exemestane ( Aromasin ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>